Neuropace Company Insiders
NPCE Stock | USD 9.35 0.20 2.09% |
Neuropace employs about 195 people. The company is managed by 17 executives with a total tenure of roughly 455 years, averaging almost 26.0 years of service per executive, having 11.47 employees per reported executive. Evaluation of Neuropace's management performance can provide insight into the firm performance.
Neuropace | Build AI portfolio with Neuropace Stock |
Neuropace Management Team Effectiveness
The company has return on total asset (ROA) of (0.1152) % which means that it has lost $0.1152 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2849) %, meaning that it created substantial loss on money invested by shareholders. Neuropace's management efficiency ratios could be used to measure how well Neuropace manages its routine affairs as well as how well it operates its assets and liabilities.Neuropace Workforce Comparison
Neuropace is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 4,958. Neuropace holds roughly 195 in number of employees claiming about 4% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.23) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.23. Neuropace Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuropace insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuropace's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neuropace insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Geiger Uri few days ago Acquisition by Geiger Uri of 2337 shares of Neuropace at 4.49 subject to Rule 16b-3 | ||
Fischer Frank M over three weeks ago Acquisition by Fischer Frank M of 2281 shares of Neuropace at 10.41 subject to Rule 16b-3 | ||
Williams Patrick F. over three weeks ago Insider Trading | ||
Martha Morrell over a month ago Disposition of 1338 shares by Martha Morrell of Neuropace at 13.54 subject to Rule 16b-3 | ||
Martha Morrell over a month ago Disposition of 3051 shares by Martha Morrell of Neuropace at 17.99 subject to Rule 16b-3 | ||
Rebecca Kuhn over two months ago Disposition of 237 shares by Rebecca Kuhn of Neuropace at 10.94 subject to Rule 16b-3 | ||
Martha Morrell over two months ago Disposition of 237 shares by Martha Morrell of Neuropace at 10.94 subject to Rule 16b-3 | ||
Martha Morrell over three months ago Acquisition by Martha Morrell of 19850 shares of Neuropace at 12.3 subject to Rule 16b-3 |
Neuropace Notable Stakeholders
A Neuropace stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neuropace often face trade-offs trying to please all of them. Neuropace's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neuropace's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Joel Becker | President CEO | Profile | |
Rebecca Kuhn | CFO Administration | Profile | |
Irina Ridley | Chief Secretary | Profile | |
Chi Nguyen | VP Marketing | Profile | |
Kelley Nicholas | Vice Sales | Profile | |
Michael Favet | CEO Pres | Profile | |
Katie Keller | Vice Marketing | Profile | |
Patrick Williams | Chief Officer | Profile | |
Martha MD | Chief Officer | Profile | |
Mark Saxton | VP Sales | Profile | |
Leah Akin | General Secretary | Profile | |
Irene Thomas | Vice Resources | Profile | |
Martha Morrell | Chief Officer | Profile | |
Dylan John | Chief Development | Profile | |
Amy Treadwell | Vice Resources | Profile | |
Andre Marquette | Chief Officer | Profile | |
Chris Reese | Senior Sales | Profile |
About Neuropace Management Performance
The success or failure of an entity such as Neuropace often depends on how effective the management is. Neuropace management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neuropace management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neuropace management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
NeuroPace, Inc. operates as a medical device company in the United States. The company was incorporated in 1997 and is headquartered in Mountain View, California. Neuropace operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 187 people.
Please note, the presentation of Neuropace's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuropace's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuropace's management manipulating its earnings.
Neuropace Workforce Analysis
Traditionally, organizations such as Neuropace use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neuropace within its industry.Neuropace Manpower Efficiency
Return on Neuropace Manpower
Revenue Per Employee | 409.8K | |
Revenue Per Executive | 4.7M | |
Net Loss Per Employee | 139.2K | |
Net Loss Per Executive | 1.6M | |
Working Capital Per Employee | 339.4K | |
Working Capital Per Executive | 3.9M |
Complementary Tools for Neuropace Stock analysis
When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |